The longtime head of Sanofi's Genzyme unit, David Meeker, will step down and be succeeded by Bill Sibold as the Cambridge, Mass.-based group embarks on an important transition with the launch of Dupixent (dupilumab). Sanofi announced April 5 that Sibold will take the reigns as executive vice president of Sanofi Genzyme after working to prepare for the launch of Dupixent as the head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organization.
The announcement sets the stage for a significant leadership change since Meeker helped to build Genzyme over his 23-year career...





